Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Datar Cancer Genetics presenta un revolucionario análisis de sangre basado en el tumor

      Blood Test to Accurately Detect Circulating Tumor-Related Mutations

      News provided by

      Datar Cancer Genetics

      Jan 24, 2025, 01:40 ET

      Share this article

      Share this article


      -Datar Cancer Genetics presenta un revolucionario análisis de sangre informado basado en el tumor para el control de enfermedades residuales

      El análisis de sangre Target-MRD utiliza una combinación de características moleculares informadas y diagnósticas del tumor para un control personalizado, preciso y más eficaz de las enfermedades residuales moleculares.

      LONDRES y MUNICH y NUEVA DELHI, 24 de enero de 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG) anunció hoy el lanzamiento de Target-MRD, un análisis de sangre avanzado para el monitoreo de la enfermedad molecular residual (MRD) en cánceres de órganos sólidos. Target-MRD es un análisis de sangre basado en la secuenciación de próxima generación (NGS) independiente del tumor y en un ensayo de PCR digital de gotas (dd-PCR) personalizado e informado sobre el tumor.

      Continue Reading
      Blood Test to Accurately Detect Circulating Tumor-Related Mutations
      Blood Test to Accurately Detect Circulating Tumor-Related Mutations

      En los pacientes que se someten a tratamientos iniciales contra el cáncer, una pequeña cantidad de células tumorales pueden sobrevivir y persistir en el cuerpo. Esta baja "carga de enfermedad" puede provocar una recaída, que puede permanecer indetectable mediante métodos genómicos y de imagen tradicionales. La detección oportuna de esta "enfermedad residual mínima" ahora se considera fundamental para mitigar los riesgos de recurrencia.

      Target-MRD ofrece detección y seguimiento personalizados y ultrasensibles de la enfermedad residual a nivel molecular, si la hubiera, para ayudar a los oncólogos a intervenir de forma temprana, mucho antes de que la enfermedad se salga de control. Target-MRD combina biomarcadores agnósticos del tumor (para detectar la evolución del tumor) e informados del tumor (específicos del cáncer de un paciente), ofreciendo así una solución integral y de altísima sensibilidad para un tratamiento más eficaz de la enfermedad.

      El Dr. Timothy Crook, oncólogo médico consultor del Hospital Cromwell de Londres, afirmó: "El seguimiento de la más mínima recurrencia del cáncer en los pacientes después del tratamiento es fundamental para permitir intervenciones oportunas antes de que la enfermedad se salga de control. El enfoque dual de MRD de Datar es un avance significativo en la detección no invasiva de los primeros signos de enfermedad residual. Tiene el potencial de cambiar la forma en que tratamos a los pacientes con cáncer".

      "Este novedoso enfoque de detección de la enfermedad residual mínima, que combina estrategias basadas en el tumor y estrategias independientes del tumor, representa un avance significativo en el diagnóstico oncológico. Esta metodología innovadora mejora nuestra capacidad de proporcionar una atención verdaderamente personalizada a los pacientes con cáncer. Su sensibilidad y precisión ofrecen a los médicos herramientas muy valiosas para personalizar los tratamientos, mejorar la detección de recurrencias y optimizar los resultados a largo plazo de los pacientes. Este es un paso transformador hacia una atención oncológica verdaderamente personalizada", afirmó el Dr. Ashok Kumar Vaid, presidente de Oncología Médica del Hospital Medanta, Gurugram.

      Avanzando hacia el futuro de la oncología

      "Target-MRD refleja el compromiso de DCG con tecnologías seguras, fiables y precisas. Es la prueba de próxima generación que tiene el potencial no solo de detectar la recurrencia antes, sino también de adaptarse a los requisitos individuales de cada paciente y ayuda a personalizar las decisiones de tratamiento del cáncer", afirmó la Dra. Darshana Patil, directora sénior de Estrategia Global y Asuntos Médicos de DCG. "Con su capacidad para detectar con sensibilidad la enfermedad residual mínima, Target-MRD proporciona a los médicos la información que necesitan para tomar decisiones oportunas basadas en datos, mejorando los resultados de los pacientes y, en última instancia, transformando la forma en que se trata el cáncer". Datar Cancer Genetics es una empresa global de investigación y aplicaciones oncológicas que lidera el desarrollo de tecnologías no invasivas para mejorar la detección, el tratamiento y la gestión del cáncer. El centro de investigación oncológica de última generación de la empresa está acreditado por NABL, ISO y CAP. La empresa atiende a pacientes con cáncer en Reino Unido, la Unión Europea, Estados Unidos, CCG y la India, y cuenta con modernas instalaciones de investigación oncológica en EE.UU., Reino Unido y la India.

      Foto: https://mma.prnewswire.com/media/2602389/DGC_Blood_Test_Mutations.jpg
      Logo: https://mma.prnewswire.com/media/2602388/Datar_Cancer_Genetics_Logo.jpg

      Modal title

      Also from this source

      Datar Cancer Genetics recibe una histórica aprobación de la FDA estadounidense para CellDx-Tissue

      Datar Cancer Genetics recibe una histórica aprobación de la FDA estadounidense para CellDx-Tissue

      Datar Cancer Genetics (DCG), una empresa global de oncología de precisión, anunció hoy que su ensayo de perfil genómico integral basado en tejidos...

      Datar Cancer Genetics erhält wegweisende FDA-Zulassung in den USA für CellDx-Tissue - umfassender Genomprofiling-Test für solide Tumoren

      Datar Cancer Genetics erhält wegweisende FDA-Zulassung in den USA für CellDx-Tissue - umfassender Genomprofiling-Test für solide Tumoren

      Datar Cancer Genetics (DCG), ein weltweit tätiges Unternehmen für Präzisionsonkologie, gibt bekannt, dass sein gewebebasierter Test für umfassendes...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Medical Equipment

      Medical Equipment

      New Products & Services

      New Products & Services

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.